Inovio Pharmaceuticals Shows Market Leadership With Jump To 86 RS Rating


Inovio Pharmaceuticals (INO) saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, with an upgrade from 76 to 86.


When looking for the best stocks to buy and watch, be sure to pay attention to relative price strength.

This exclusive rating from Investor’s Business Daily measures market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock’s price movement over the trailing 52 weeks holds up against all the other stocks in our database.

History shows that the market’s biggest winners often have an RS Rating north of 80 in the early stages of their moves.

Looking For The Best Stocks To Buy And Watch? Start Here

Inovio Pharmaceuticals has risen more than 5% past an 11.69 entry in a second-stage cup with handle, meaning it’s now out of a proper buy range. Look for the stock to offer a new chance to pick up shares like a three-weeks tight or pullback to the 50-day or 10-week moving average. Read “Looking For The Next Big Stock Market Winners? Start With These 3 Steps” for more tips.

Earnings growth rose last quarter from 0% to 147%. But sales fell from 93% to -72%. The company is expected to report its latest earnings and sales numbers on or around Mar. 12.

The company earns the No. 315 rank among its peers in the Medical-Biomed/Biotech industry group. Horizon Pharma (HZNP) and Avid Bioservices (CDMO) are also among the group’s highest-rated stocks. For more industry news, check out “Biotech And Pharma Industry And Stock News.”


MarketSmith’s Tools Can Help The Individual Investor

IBD Live: A New Tool For Daily Stock Market Analysis

Profit From Short-Term Trends With SwingTrader

How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks